Stabilized live attenuated vaccine and its production
US4985244A · kind A · utility
22Cited by
3References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 8, 1988 |
| Grant date | Jan 15, 1991 |
| Priority date | — |
| Expiry date | Jun 8, 2008 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/36234
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A stabilized live attenuated vaccine with improved thermal stability, which comprises a live attenuated plain vaccine consisting of measles, mumps or rubella virus grown in a medium-199 for cell culture, or a combined live attenuated vaccine thereof, containing a stabilizing agent at a final concentration of lactose 2.5-5 W/V %, saccharose 2.5-5 W/V %, D-sorbitol 1.8-2 W/V %, sodium glutamate about 0.1 W/V % and gelatin hydrolyzate, M.W. approx. 35,000, 2-3 W/V %.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.